Paul Tudor Jones Kal Vista Pharmaceuticals, Inc. Transaction History
Tudor Investment Corp Et Al
- $200 Billion
- Q3 2025
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Kal Vista Pharmaceuticals, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 2,000,000 shares of KALV stock, worth $26.6 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,000,000Holding current value
$26.6 Million% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding KALV
# of Institutions
156Shares Held
59.9MCall Options Held
1.21MPut Options Held
865K-
Vr Adviser, LLC New York, NY6.73MShares$89.6 Million12.35% of portfolio
-
Tang Capital Management LLC San Diego, CA5.04MShares$67.2 Million2.77% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA5.04MShares$67.1 Million2.57% of portfolio
-
Suvretta Capital Management, LLC New York, NY4.77MShares$63.5 Million1.73% of portfolio
-
Capital World Investors Los Angeles, CA3.18MShares$42.3 Million0.01% of portfolio
About KalVista Pharmaceuticals, Inc.
- Ticker KALV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,602,000
- Market Cap $328M
- Description
- KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...